ABCG2 and lung cancer: Encouragingly, however, a protein kinase AKT1/2/3 inhibitor, MK-2206, has been shown to reverse the ABCG2-mediated MDR response of lung cancer cells to mitoxantrone, SN-38 and topotecan (116).